US$ 27.25
glp-1 masld Comparative Analysis of Resmetirom vs. FGF21 Analogs vs. Agonists in and MASH: Network Meta-Analysis of Clinical Trials Hepatokines and MASLD: The GLP1-Ras-FGF21-Fetuin-A
Description
Food and Drug Administration, FDA, 8 Nov

Glucagon-like peptide 1 receptor activation attenuates platelet aggregation and thrombosis

Patients who lose 1520% of body weight and maintain strict dietary habits may sustain results with lower doses or longer intervals between injections

FEBS Letters, 583 (22), 36973703

The best candidates are usually individuals aged 55 or older who have at least two cardiovascular risk factors such as obesity, high blood pressure, smoking, high cholesterol, or protein in the urine or those already diagnosed with atherosclerotic cardiovascular disease
